Heparin-induced thrombocytopenia (HIT II) - A drug-associated autoimmune disease

Thrombosis and Haemostasis

Volumn 102, Issue 5, 2009, Pages 887-891

  Nowak, Götz ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Autoimmune disease; HIT II; IgG antibody; PADA HIT

Indexed keywords

ANTIBODY; FC RECEPTOR IIA; HEPARIN; IMMUNOGLOBULIN G ANTIBODY; THROMBOCYTE FACTOR 4;

ADULT; AGED; ANTIBODY DETECTION; ASSAY; AUTOIMMUNE DISEASE; AUTOIMMUNE THROMBOCYTOPENIA; BLOOD EXAMINATION; CARDIAC PATIENT; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; HEMODIALYSIS PATIENT; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PLATELET ADHESION ASSAY; PRIORITY JOURNAL; STROKE PATIENT; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION;

ADULT; AGED; ANTICOAGULANTS; AUTOANTIBODIES; CITRATES; EARLY DIAGNOSIS; FEMALE; HEART DISEASES; HEPARIN; HUMANS; IMMUNOGLOBULIN G; KIDNEY FAILURE, CHRONIC; MALE; MODELS, IMMUNOLOGICAL; PLATELET ADHESIVENESS; PLATELET COUNT; PLATELET FACTOR 4; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, IGG; RENAL DIALYSIS; STROKE;

EID: 70449572934     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-03-0209     Document Type: Conference Paper

References (16)

1. th Edition). Chest 2008; 133: 340S-380S.
2. Davoren A, Ster RH. Heparin-induced thrombocytopenia and thrombosis. Am J Hematol 2006; 81: 36-44.
3. Kanaan AO, Al-Homsi AS. Heparin-induced thrombocytopenia: pathophysiology, diagnosis, and review of pharmacotherapy. J Pharm Pract 2009; 22: 149-157.
4. Zinkowsky DA, Antonopoulos MS. Heparin-induced thrombocytopenia: overview and treatment. PT 2008; 33: 642-652.
5. Bennett-Guerrero E, Slaugher TF, White WD, et al. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 2005; 130: 1567-1572. (Pubitemid 41676920)
6. Greinacher A, Juhl D, Strobel U, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of platelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007; 5: 1666-1673. (Pubitemid 47091409)
7. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 311-337. (Pubitemid 39297959)
8. Greinacher A, Levy IH. HIT happens: diagnosing and evaluating the patient with heparin-induced thrombocytopenia. Anaesth Analg 2008; 107: 356-358.
9. Rosenberg N, Einav Y, Shenkman B. Autoimmune Thrombocytopenic Purpura. In: Diagnostic Criteria in Autoimmune Diseases. Humana Press, Totowa (USA), 2008, pp. 543-546.
10. Blank M, Shoenfeld Y, Tavor S, et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 2002; 14: 121-129. (Pubitemid 34144736)
11. Warkentin TE, Kelton JG. Temporal aspects of heparin- induced thrombocytopenia. N Engl J Med 2001; 344: 1286-1292. (Pubitemid 32372963)
12. Greinacher A, Kohlmann T, Strobel U, et al. The temporal profile of the anti-PF/heparin immune response. Blood 2009; 113: 4970-4976.
13. Chan M, Malynn E, Shaz B, et al. Utility of consecutive repeat HIT ELISA testing for heparin-induced thrombocytopenia. Am J Hemat 2008; 83: 420-423.
14. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355: 809-817.
15. Aster RH. Heparin-independent activation of platelets by HIT antibodies: a clue to the etiology of delayed thrombocytopenia/thrombosis in patients given heparin? J Thromb Haemost 2005; 3: 2166-2167.
16. Ulbricht K, Bucha E, Pöschel KA, et al. The use of PEG-Hirudin in chronic hemodialysis monitored by the Ecarin Clotting Time: influence on clotting of the extracorporeal system and hemostatic parameters. Clin Nephrol 2006; 65: 180-190. (Pubitemid 43337997)